Replies to post #410256 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Anavex might still perform somewhat better than Aricept and simufilam for mild cognitive impairment and mild Alzheimer’s disease because in addition to being a sigma-1 receptor agonist, it may also acts as a direct antioxidant. More importantly that combination can potentially almost stabilize early stage Alzheimer’s disease for at least two to three years. For that reason, Anavex likely remains a good investment, despite underlying issues regarding its data.

https://seekingalpha.com/article/4592603-biogen-and-eisai-cassava-sciences-and-anavex-clinical-trial-results-in-need-of-revisions

Good luck and GOD bless,